Condition: Prostate Cancer · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or \[177Lu\]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Urology Centers Of Alabama Pc | Homewood, Alabama, United States | Recruiting |
| Stanford University Medical Center | Palo Alto, California, United States | Recruiting |
| Sansum Clinic | Santa Barbara, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | Recruiting |
| Florida Cancer Specialists | Fort Myers, Florida, United States | Recruiting |
| Baptist Health South | Miami, Florida, United States | Recruiting |
| AdventHealth | Orlando, Florida, United States | Recruiting |
| University Cancer and Blood Center LLC | Athens, Georgia, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Univ Of Iowa Hospitals And Clinics | Iowa City, Iowa, United States | Recruiting |
| University of Kansas Hospital | Kansas City, Kansas, United States | Recruiting |
| East Jefferson Hospital | Metairie, Louisiana, United States | Recruiting |
+ 76 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06855277